Boardroom Talk: Summit Therapeutics' long road to drug approval

Summit Therapeutics is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.Investors' Chronicle has supported private investors in the UK for over 160 years by highlighting rewarding investment opportunities. Investors' Chronicle is a service by the Financial Times. Hosted on Acast. See acast.com/privacy for more information.

Episode metadata supplied by the publisher feed · Published Mar 20, 2017

Embed this episode

Attribution link and audio player

NOW PLAYING

Boardroom Talk: Summit Therapeutics' long road to drug approval

0:00 14:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Investors' Chronicle?

This episode is 14 minutes long.

When was this Investors' Chronicle episode published?

This episode was published on March 20, 2017.

Can I download this Investors' Chronicle episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!